Merck & Co., Inc. (MRK) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Merck & Company, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.595 Thank you for standing by. Welcome to the Merck and Company Inc. 00:00:03.595 -- 00:00:08.079 Raleigh, New Jersey, USA Q2 Sales and Earnings Conference call. 00:00:08.079 -- 00:00:11.623 At this time, all participants are in the listen-only mode until the question and answer 00:00:11.623 -- 00:00:16.348 session of today's conference. At that time, to ask a question, press star 1 on your 00:00:16.348 -- 00:00:20.552 phone and record your name at the prompt. This call is being recorded. 00:00:20.552 -- 00:00:23.014 If you have any objections, you may disconnect at this time. 00:00:23.014 -- 00:00:25.757 I will now turn the conference over to Mr. 00:00:25.757 -- 00:00:29.115 Peter Dannenbaum. Senior Vice President, Investor Relations. 00:00:29.115 -- 00:00:29.976 Sir, you may begin. 00:00:29.976 -- 00:00:31.976 Thank 00:00:32.139 -- 00:00:36.404 you, Shirley, and good morning, everyone. Welcome to the second quarter 2025 conference 00:00:36.404 -- 00:00:40.189 call for Merck and Company Incorporated, Rahway, New Jersey, USA. 00:00:40.189 -- 00:00:44.755 Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer, Caroline 00:00:44.755 -- 00:00:47.138 Litchfield, Chief Financial Officer, and Dr. 00:00:47.138 -- 00:00:51.607 Dean Lee, President of Research Labs. Before we get started, I'd like to point out that 00:00:51.607 -- 00:00:55.171 we have items in our GAAP results, such as acquisition-related charges, restructuring 00:00:55.171 -- 00:00:59.056 costs, and certain other items that we have excluded from our non-GAAP results. 00:00:59.056 -- 00:01:01.859 There is a reconciliation in our press release. 00:01:01.859 -- 00:01:04.822 I will also remind you that some of the statements that we make today may be consi...